4,6-二甲基-3-(4-嘧啶-2-基哌嗪-1-基)哒嗪 | 923951-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4,6-二甲基-3-(4-嘧啶-2-基哌嗪-1-基)哒嗪
• 英文名称: 2-(4-(4,6-dimethylpyridazin-3-yl)piperazin-1-yl)pyrimidine
• 英文别名: 4,6-Dimethyl-3-[4-(pyrimidin-2-yl)piperazin-1-yl]pyridazine；4,6-dimethyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine
• CAS: 923951-09-1
• 化学式: C₁₄H₁₈N₆
• 分子量: 270.337
• InChiKey: AIFXNMZCEOYIAA-UHFFFAOYSA-N

物化性质

• 沸点：
  541.4±60.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-氯-4-甲基-3-哒嗪酮 在 N-甲基吡咯烷酮 、 iron(III)-acetylacetonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 4,6-二甲基-3-(4-嘧啶-2-基哌嗪-1-基)哒嗪
  参考文献：
  名称：

  Identification of Aminopyridazine-Derived Antineuroinflammatory Agents Effective in an Alzheimer's Mouse Model

  摘要：

  Targeting neuroinflammation may be a new strategy to combat Alzheimer's disease. An aminopyridazine 1b previously reported as a novel antineuroinflammatory agent was considered to have a potential therapeutic effect for Alzheimer's disease. In this study, we further explored the chemical space to identify more potent antineuroinflammatory agents and validate their in vivo efficacy in an animal model. Compound 14 was finally identified as an effective agent with comparable in vivo efficacy to the marketed drug donepezil in counteracting spatial learning and working memory impairment in an A beta-induced Alzheimer's mouse model.

  DOI：

  10.1021/ml3001769

文献信息

• Pyridazine Compounds, Compositions and Methods
  申请人：Watterson Martin

  公开号：US20080318899A1

  公开（公告）日：2008-12-25

  The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及新型化合物和制备和使用它们的方法。具体而言，本发明提供吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及使用吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS
  申请人：Watterson D. Martin

  公开号：US20120245125A1

  公开（公告）日：2012-09-27

  The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications.

  本发明涉及新型化合物、组合物及其制备和使用的方法。特别是，本发明提供了吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及制备和使用这些吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS
  申请人：WATTERSON D. Martin

  公开号：US20120157410A1

  公开（公告）日：2012-06-21

  The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及含有吡啶二氮化合物和胆碱酯酶抑制剂的组合物、共轭物和方法，用于调节细胞途径（例如，信号转导途径），用于治疗或预防炎症性疾病（例如，阿尔茨海默病），用于研究、药物筛选和治疗应用。
• Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits
  作者：Wenhui Hu、Hantamalala Ralay Ranaivo、Saktimayee M. Roy、Heather A. Behanna、Laura K. Wing、Lenka Munoz、Ling Guo、Linda J. Van Eldik、D. Martin Watterson

  DOI：10.1016/j.bmcl.2006.10.028

  日期：2007.1

  We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders. (c) 2006 Elsevier Ltd. All rights reserved.
• COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS
  申请人：Watterson Martin D.

  公开号：US20100210590A1

  公开（公告）日：2010-08-19

  The present invention relates to therapeutic and/or prophylactic uses of pyridazine compounds and to pharmaceutical compositions containing one or more of these compounds as an active component for treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, in particular epilepsy, more particularly pediatric epilepsy. In an aspect of the invention, the pyridnsine compound has the Formula (Ia) or (Ib) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the description.